Neuraxis Inc. (NRXS)
NRXS trades on NYSE in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1933567/000149315226011505/0001493152-26-011505-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NRXS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001933567 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.6M |
| Net income | -$7.8M |
| Operating income | -$7.8M |
| Net margin | -218.5% |
| Operating margin | -219.4% |
| Revenue growth | +32.9% |
| Cash | $5.0M |
| Total assets | $6.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 19.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, substantial doubt is deemed to exist about the Company's ability to continue as a going concern." | 10-Q 2026-11-09 |
| Cash and burn | $4.5M cash; operating cash flow -$1.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 14,193,209 (2026-11-06); 10,652,812 a year earlier; 5,289,514 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.4M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.0M | -$6.5M | -$2.3M | $4.5M | $415K | $6.5M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $1.9M | -$2.1M | -$1.0M | $8.3M | $85K | $5.3M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $1.6M | -$1.8M | -$1.2M | $7.1M | $201K | $4.3M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $968K | -$1.7M | -$1.9M | $5.0M | $297K | $3.6M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $811K | -$2.1M | -$1.4M | $4.4M | $196K | $3.4M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $894K | -$1.7M | -$1.5M | $6.0M | $121K | $3.2M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $896K | -$2.3M | -$1.6M | $2.0M | $84K | $2.9M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $761K | -$1.4M | -$1.8M | $3.7M | $308K | $2.7M | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-06 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-10-14 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 196 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.1% |
| 1 month | -16.6% |
| 3 months | -13.7% |
| Year to date | +19.4% |
| 1 year | +130.6% |
| From 52-week high | -38.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HYPR | Hyperfine Inc. | $0.6101 | -3.05% | $64.8M |
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier